All Stories

  1. Therapeutic expression of human clotting factors IX and × following adeno‐associated viral vector‐mediated intrauterine gene transfer in early‐gestation fetal macaques
  2. Vps33b is crucial for structural and functional hepatocyte polarity
  3. Lentiviral vectors can be used for full-length dystrophin gene therapy
  4. Delivering efficient liver-directed AAV-mediated gene therapy
  5. The Local and Systemic Immune Response to Intrauterine LPS in the Prepartum Mouse
  6. Regulation of post-Golgi LH3 trafficking is essential for collagen homeostasis
  7. Modeling hormonal and inflammatory contributions to preterm and term labor using uterine temporal transcriptomics
  8. NRF2 Orchestrates the Metabolic Shift during Induced Pluripotent Stem Cell Reprogramming
  9. A Broad Overview and Review of CRISPR-Cas Technology and Stem Cells
  10. Gene Therapy with Adeno-associated Virus for Cystic Fibrosis
  11. Proof-of-concept: neonatal intravenous injection of adeno-associated virus vectors results in successful transduction of myenteric and submucosal neurons in the mouse small and large intestine
  12. Specific Lipopolysaccharide Serotypes Induce Differential Maternal and Neonatal Inflammatory Responses in a Murine Model of Preterm Labor
  13. Specific inhibition of c-Jun N-terminal kinase delays preterm labour and reduces mortality
  14. In vivo bioimaging with tissue-specific transcription factor activated luciferase reporters
  15. Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates
  16. Evidence for Contribution of CD4+CD25+ Regulatory T Cells in Maintaining Immune Tolerance to Human Factor IX following Perinatal Adenovirus Vector Delivery
  17. Perinatal systemic gene delivery using adeno-associated viral vectors
  18. The Human Desmin Promoter Drives Robust Gene Expression for Skeletal Muscle Stem Cell-Mediated Gene Therapy
  19. Regionally-Specified Second Trimester Fetal Neural Stem Cells Reveals Differential Neurogenic Programming
  20. Hyperactive PiggyBac Transposons for Sustained and Robust Liver-targeted Gene Therapy
  21. Activator protein 1 is a key terminal mediator of inflammation-induced preterm labor in mice
  22. Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction
  23. Transduction of Fetal Mice With a Feline Lentiviral Vector Induces Liver Tumors Which Exhibit an E2F Activation Signature
  24.  -Glucosidase 2 (GBA2) Activity and Imino Sugar Pharmacology
  25. Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease
  26. Erratum to: Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes
  27. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
  28. Exon Skipping of Hepatic APOB Pre-mRNA With Splice-switching Oligonucleotides Reduces LDL Cholesterol In Vivo
  29. Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes
  30. The Fetal Mouse Is a Sensitive Genotoxicity Model That Exposes Lentiviral-associated Mutagenesis Resulting in Liver Oncogenesis
  31. The CD46-Jagged1 interaction is critical for human TH1 immunity
  32. The case for intrauterine gene therapy
  33. Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems
  34. Prenatal Gene Therapy
  35. Monitoring for Potential Adverse Effects of Prenatal Gene Therapy: Use of Large Animal Models with Relevance to Human Application
  36. Monitoring for Potential Adverse Effects of Prenatal Gene Therapy: Mouse Models for Developmental Aberrations and Inadvertent Germ Line Transmission
  37. Choice of Surrogate and Physiological Markers for Prenatal Gene Therapy
  38. Animal Models for Prenatal Gene Therapy: Rodent Models for Prenatal Gene Therapy
  39. Candidate Diseases for Prenatal Gene Therapy
  40. The Concept of Prenatal Gene Therapy
  41. Vector Systems for Prenatal Gene Therapy: Choosing Vectors for Different Applications
  42. AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage
  43. In utero administration of Ad5 and AAV pseudotypes to the fetal brain leads to efficient, widespread and long-term gene expression
  44. Stable Human FIX Expression After 0.9G Intrauterine Gene Transfer of Self-complementary Adeno-associated Viral Vector 5 and 8 in Macaques
  45. Perinatal Gene Transfer to the Liver
  46. Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system
  47. Fetal gene therapy: recent advances and current challenges
  48. Organ targeted prenatal gene therapy-how far are we?
  49. Recombinant Adeno-Associated Virus-Mediated In Utero Gene Transfer Gives Therapeutic Transgene Expression in the Sheep
  50. Recent advances in fetal gene therapy
  51. Perinatal gene delivery to the CNS
  52. Development of S/MAR minicircles for enhanced and persistent transgene expression in the mouse liver
  53. Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid Proteins
  54. In utero gene transfer to the mouse nervous system: Figure 1
  55. Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis
  56. Codon optimization of human factor VIII cDNAs leads to high-level expression
  57. Gene Delivery of a Mutant TGFβ3 Reduces Markers of Scar Tissue Formation After Cutaneous Wounding
  58. Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease
  59. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors
  60. Neonatal Gene Therapy of Glycogen Storage Disease Type Ia Using a Feline Immunodeficiency Virus–based Vector
  61. Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control
  62. Desmin-regulated Lentiviral Vectors for Skeletal Muscle Gene Transfer
  63. The differentiation and engraftment potential of mouse hematopoietic stem cells is maintained after bio-electrospray
  64. LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives
  65. Activation and deactivation of periventricular white matter phagocytes during postnatal mouse development
  66. Erratum to “Influence of Coagulation Factor X on In Vitro and In Vivo Gene Delivery by Adenovirus (Ad) 5, Ad35, and Chimeric Ad5/Ad35 Vectors”
  67. Influence of Coagulation Factor X on In Vitro and In Vivo Gene Delivery by Adenovirus (Ad) 5, Ad35, and Chimeric Ad5/Ad35 Vectors
  68. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer
  69. Differentiation of human fetal mesenchymal stem cells into cells with an oligodendrocyte phenotype
  70. The Cyclopentenone 15-Deoxy-Δ12,14-Prostaglandin J2Delays Lipopolysaccharide-Induced Preterm Delivery and Reduces Mortality in the Newborn Mouse
  71. Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors
  72. Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer
  73. Luciferin Detection After Intranasal Vector Delivery Is Improved by Intranasal Rather Than Intraperitoneal Luciferin Administration
  74. Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector
  75. Genetic aspects and research development in haemostasis
  76. Lentiviral transduction of the murine lung provides efficient pseudotype and developmental stage-dependent cell-specific transgene expression
  77. Intra-amniotic Delivery of CFTR-expressing Adenovirus Does Not Reverse Cystic Fibrosis Phenotype in Inbred CFTR-knockout Mice
  78. Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer
  79. Stable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors
  80. The Influence of Blood on In Vivo Adenovirus Bio-distribution and Transduction
  81. Targeting of Adenovirus Serotype 5 (Ad5) and 5/47 Pseudotyped Vectors In Vivo: Fundamental Involvement of Coagulation Factors and Redundancy of CAR Binding by Ad5
  82. Widespread Distribution and Muscle Differentiation of Human Fetal Mesenchymal Stem Cells After Intrauterine Transplantation in DystrophicmdxMouse
  83. Influence of Coagulation Factor Zymogens on the Infectivity of Adenoviruses Pseudotyped with Fibers from Subgroup D
  84. Delivery and long-term expression of a 135 kbLDLR genomic DNA locusin vivo by hydrodynamic tail vein injection
  85. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes
  86. Evaluation of prenatal intra-amniotic LAMB3 gene delivery in a mouse model of Herlitz disease
  87. Clinically Applicable Procedure for Gene Delivery to Fetal Gut by Ultrasound-Guided Gastric Injection: Toward Prenatal Prevention of Early-Onset Intestinal Diseases
  88. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver
  89. Corrigendum to "Oncogenesis Following Delivery of a Nonprimate Lentiviral Gene Therapy Vector to Fetal and Neonatal Mice"
  90. Oncogenesis Following Delivery of a Nonprimate Lentiviral Gene Therapy Vector to Fetal and Neonatal Mice
  91. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX
  92. Targeting the respiratory muscles of fetal sheep for prenatal gene therapy for Duchenne muscular dystrophy
  93. Gene Therapy Progress and Prospects: Fetal gene therapy – first proofs of concept – some adverse effects
  94. Factors Influencing Adenovirus-Mediated Airway Transduction in Fetal Mice
  95. In Utero gene therapy: current challenges and perspectives
  96. No evidence for germ-line transmission following prenatal and early postnatal AAV-mediated gene delivery
  97. Complement inhibition rescued mice allowing observation of transgene expression following intraportal delivery of baculovirus in mice
  98. Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy
  99. Fetal and neonatal gene therapy: benefits and pitfalls
  100. Highly efficient EIAV-mediated in utero gene transfer and expression in the major muscle groups affected by Duchenne muscular dystrophy
  101. Reduced toxicity of F-deficient Sendai virus vector in the mouse fetus
  102. Widespread and efficient marker gene expression in the airway epithelia of fetal sheep after minimally invasive tracheal application of recombinant adenovirus in utero
  103. The Hopes and Fears of In Utero Gene Therapy for Genetic Disease—A Review
  104. Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice
  105. Ultrasound-Guided Percutaneous Delivery of Adenoviral Vectors Encoding the -Galactosidase and Human Factor IX Genes to Early Gestation Fetal Sheep In Utero
  106. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor
  107. Arginase in glomerulonephritis
  108. Sustained delivery of therapeutic concentrations of human clotting factor IX - a comparison of adenoviral and AAV vectors administeredin utero
  109. Arginase in Glomerulonephritis
  110. Induced nitric oxide (NO) synthesis in heterologous nephrotoxic nephritis; effects of selective inhibition in neutrophil-dependent glomerulonephritis
  111. Arginase AI Is Upregulated in Acute Immune Complex-Induced Inflammation
  112. Anti-GBM glomerulonephritis in mice lacking nitric oxide synthase type 2 Rapid Communication